Atlas Trials

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Clinical trial NCT00903175 · COMPLETED

Trial details

NCT number
NCT00903175
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2009-10-01
Primary completion
2015-05-01
Enrollment
471

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.